Originally published at sanofi.com. Sanofi U.S. ranked No. 27 on The Fair360, formerly DiversityInc Top 50 Companies for Diversity list in 2021.
On Nov. 18, Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programs in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments. Owkin, an artificial intelligence (AI) and precision medicine company, builds best-in-class predictive biomedical AI models and robust data sets. With the ambition to optimize clinical trial design and detect predictive biomarkers for diseases and treatment outcomes, this collaboration will support Sanofi’s growing oncology portfolio in core areas such as lung cancer, breast cancer and multiple myeloma.
To accelerate medical research with AI in a privacy-preserving way, Owkin has assembled a global research network powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets and train AI models without having to pool data. This approach will complement Sanofi’s emerging strength in oncology, as the company’s scientists apply cutting-edge technology platforms to design potentially life-transforming medicines for cancer patients worldwide.
“Owkin’s unique methodology, which applies AI on patient data from partnerships with multiple academic medical centers, supports our ambition to leverage data in innovative ways in R&D,” said Arnaud Robert, Executive Vice President, Chief Digital Officer, Sanofi. “We are striving to advance precision medicine to the next level and to discover innovative treatment methods with the greatest benefits for patients.”
Sanofi will leverage the comprehensive Owkin Platform, in order to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment from multimodal patient data. Sanofi’s investment will support Owkin’s development and goal to grow the world’s leading histology and genomic cancer database from top oncology centers.
“Owkin’s mission is to improve patients’ lives by using our platform to discover and develop the right treatment for every patient,” said Thomas Clozel, M.D., Co-Founder and CEO at Owkin. “We believe that the future of precision medicine lies in technologies that can unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way. This landmark partnership with Sanofi will see federated learning used to create research collaborations at a truly unprecedented scale. The future of AI to transform how we develop treatments is incredibly bright, and we are proud to partner with Sanofi on this mission.”
This collaboration agreement will allow Sanofi to work closely with Owkin in identifying new oncology treatments across four cancers.
“We look forward to working with our colleagues at Owkin to analyze data from hundreds of thousands of patients,” said John Reed, M.D., Ph.D., Global Head of Research and Development, Sanofi. “Sanofi’s investment in the company includes a three-year agreement that will help discover and develop new treatments for non-small cell lung cancer, triple-negative breast cancer, mesothelioma and multiple myeloma. This partnership will help accelerate our ambitious oncology program as we advance a rich pipeline of medicines to address unmet patient needs.”
